CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy
Histopathology · 2023
DOI: 10.1111/his.14910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Mario L Marques-Piubelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T‐cells anti‐CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of patients who relapsed after this therapy. This is the first study to show decreased CD30 expression in R/R CHL in patients ( n = 5) who underwent CAR T‐cell therapy in our institution between 2018 and 2022. Although conventional immunohistochemical assays showed decreased CD30 expression in neoplastic cells in all cases (8/8) the tyramide amplification assay and RNAScope in situ hybridisation detected CD30 expression at different levels in 100% ( n = 8/8) and 75% ( n = 3/4), respectively. Hence, our findings document that certain levels of CD30 expression are retained by the neoplastic cells. This is not only of biological interest but also diagnostically important, as detection of CD30 is an essential factor in establishing a diagnosis of CHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Mario L Marques-Piubelli, L Jeffrey Medeiros, Francisco Vega
Förderung
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Marques-Piubelli, M. L., Kim, D. H., Medeiros, L. J., Lu, W., Khan, K., Gomez-Bolanos, L. I., Rodriguez, S., Parra, E. R., Ok, C. Y., Aradhya, A., Solis, L. M., Nieto, Y. L., Steiner, R., Ahmed, S., & Vega, F. (2023). CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy. Histopathology. https://doi.org/10.1111/his.14910
Vancouver
Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, et al. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy. Histopathology. 2023. doi:10.1111/his.14910
BibTeX
@article{MarquesPiubelli2023,
author = {Marques-Piubelli, Mario L and Kim, Do Hwan and Medeiros, L Jeffrey and Lu, Wei and Khan, Khaja and Gomez-Bolanos, Lorena Isabel and Rodriguez, Saxon and Parra, Edwin R and Ok, Chi Young and Aradhya, Akanksha and Solis, Luisa M and Nieto, Yago L and Steiner, Raphael and Ahmed, Sairah and Vega, Francisco},
title = {CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.14910}
}
EUVIMED